4D Molecular Therapeutics (FDMT) Net Income towards Common Stockholders (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Net Income towards Common Stockholders of -$68.8 million for Q1 2026, down 43.33% year-over-year from -$121.3 million in Q1 2025, and down 454.49% quarter-over-quarter from $19.4 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Net Income towards Common Stockholders for 7 consecutive years, with -$68.8 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 43.33% year-over-year to -$68.8 million; the TTM figure through Mar 2026 stood at -$160.9 million (up 8.81% YoY), while the FY2025 annual figure was -$140.1 million, up 12.9% from the prior year.
- Net Income towards Common Stockholders declined to -$68.8 million in Q1 2026 per FDMT's latest filing, from $19.4 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $19.4 million in Q4 2025 and bottomed at -$68.8 million in Q1 2026.
- Historically, Net Income towards Common Stockholders has averaged -$34.0 million across 5 years, with a median of -$32.3 million in 2023.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders tumbled 327.49% — and 2025, when it soared 139.05%.
- 4D Molecular Therapeutics' Net Income towards Common Stockholders stood at -$27.4 million in 2022, then decreased by 17.91% to -$32.3 million in 2023, then plunged by 53.86% to -$49.7 million in 2024, then soared by 139.05% to $19.4 million in 2025, then plunged by 454.49% to -$68.8 million in 2026.
- Business Quant data shows FDMT's Net Income towards Common Stockholders at -$68.8 million in Q1 2026, $19.4 million in Q4 2025, and -$56.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | -72.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -72.94 Mn |
| Mar 31, 2026 | -68.76 Mn |
| Dec 31, 2025 | 19.40 Mn |
| Sep 30, 2025 | -56.88 Mn |
| Jun 30, 2025 | -54.66 Mn |
| Mar 31, 2025 | -47.97 Mn |
| Dec 31, 2024 | -49.67 Mn |
| Sep 30, 2024 | -43.84 Mn |
| Jun 30, 2024 | -34.95 Mn |
| Mar 31, 2024 | -32.40 Mn |
| Dec 31, 2023 | -32.28 Mn |
| Sep 30, 2023 | -10.26 Mn |
| Jun 30, 2023 | -29.62 Mn |
| Mar 31, 2023 | -28.68 Mn |
| Dec 31, 2022 | -27.38 Mn |
| Sep 30, 2022 | -25.69 Mn |
| Jun 30, 2022 | -28.09 Mn |
| Mar 31, 2022 | -26.34 Mn |
| Dec 31, 2021 | -25.08 Mn |
| Sep 30, 2021 | -22.24 Mn |